Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Hepatocellular carcinoma (HCC) is the second-most-common cause of cancer-related deaths worldwide, and an accurate and non-invasive biomarker for the early detection and monitoring of HCC is required. We assessed pathogenic variants of HCC driver genes in cell-free DNA (cfDNA) from HCC patients who had not undergone systemic therapy. Methods: Plasma cfDNA was collected from 20 HCC patients, and deep sequencing was performed using a customized cfDNA next-generation sequencing panel, targeting the major HCC driver genes (TP53, CTNNB1, TERT) that incorporates molecular barcoding. Results: In 13/20 (65%) patients, we identified at least one pathogenic variant of two major HCC driver genes (TP53 and CTNNB1), including 16 variants of TP53 and nine variants of CTNNB1. The TP53 and CTNNB1 variants showed low allele frequencies, with median values of 0.17% (range: 0.06%-6.99%) and 0.07% (range: 0.05%–0.96%), respectively. However, the molecular coverage of variants was sufficient, with median values of 5,543 (range: 2,317–9,088) and 7,568 (range: 2,400–9,633) for TP53 and CTNNB1 variants, respectively. Conclusions: Our targeted DNA sequencing successfully identified low-frequency pathogenic variants in the cfDNA from HCC patients by achieving high coverage of unique molecular families. Our results support the utility of cfDNA analysis to identify somatic gene variants in HCC patients.
Abstract
Background: Hepatocellular carcinoma (HCC) is the second-most-common cause of cancer-related deaths worldwide, and an accurate and non-invasive biomarker for the early detection and monitoring of HCC is required. We assessed pathogenic variants of HCC driver genes in cell-free DNA (cfDNA) from HCC patients who had not undergone systemic therapy. Methods: Plasma cfDNA was collected from 20 HCC patients, and deep sequencing was performed using a customized cfDNA next-generation sequencing panel, targeting the major HCC driver genes (TP53, CTNNB1, TERT) that incorporates molecular barcoding. Results: In 13/20 (65%) patients, we identified at least one pathogenic variant of two major HCC driver genes (TP53 and CTNNB1), including 16 variants of TP53 and nine variants of CTNNB1. The TP53 and CTNNB1 variants showed low allele frequencies, with median values of 0.17% (range: 0.06%-6.99%) and 0.07% (range: 0.05%–0.96%), respectively. However, the molecular coverage of variants was sufficient, with median values of 5,543 (range: 2,317–9,088) and 7,568 (range: 2,400–9,633) for TP53 and CTNNB1 variants, respectively. Conclusions: Our targeted DNA sequencing successfully identified low-frequency pathogenic variants in the cfDNA from HCC patients by achieving high coverage of unique molecular families. Our results support the utility of cfDNA analysis to identify somatic gene variants in HCC patients.
참고문헌 (25)
- Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Zhaleh Farokhizadeh, "Association of MicroRNA Polymorphisms With Hepatocellular Carcinoma in an Iranian Population", Annals of Laboratory Medicine, 39(1), pp.58~66 (2019), 대한진단검사의학회[DOI]
- Ju Dong Yang, "Detect or not to detect very early stage hepatocellular carcinoma? The western perspective", Clinical and Molecular Hepatology, 25(4), pp.335~343 (2019), 대한간학회
- Yang K, "Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response", HPB (Oxford), 21, pp.1718~1726 (2019)
- Sung PS, "Long-term outcome of liver resection versus transplantation for hepatocellular carcinoma in a region where living donation is a main source", Ann Transplant, 22, pp.276~284 (2017)
- Li VD, "TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database", J Cancer Res Clin Oncol, 145, pp.625~636 (2019)
- Khemlina G, "The biology of hepatocellular carcinoma: implications for genomic and immune therapies", Mol Cancer, 16, pp.149~ (2017)
- Huang Z, "Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma", Pathol Oncol Res, 18, pp.271~276 (2012)
- Yang YJ, "Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction", Clin Invest Med, 34, pp.E238~ (2011)
- Schulze K, "Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets", Nat Genet, 47, pp.505~511 (2015)
- Totoki Y, "Trans-ancestry mutational landscape of hepatocellular carcinoma genomes", Nat Genet, 46, pp.1267~1273 (2014)
- Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2008)
- Bryan C. Ulrich, "Cell-Free DNA in Oncology: Gearing up for Clinic", Annals of Laboratory Medicine, 38(1), pp.1~8 (2018), 대한진단검사의학회
- Vollbrecht C, "Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients", Oncotarget, 9, pp.18529~18539 (2018)
- Cancer Genome Atlas Research Network, "Comprehensive and integrative genomic characterization of hepatocellular carcinoma", Cell, 169, pp.1327~1341.e23 (2017)
- Fujimoto A, "Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer", Nat Genet, 48, pp.500~509 (2016)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- 정태동, "Effects of Pre-analytical Variables on Cell-free DNA Extraction for Liquid Biopsy", Laboratory Medicine Online, 9(2), pp.45~56 (2019), 대한진단검사의학회[DOI]
- He HJ, "Multilaboratory assessment of a new reference material for quality assurance of cell-free tumor DNA measurements", J Mol Diagn, 21, pp.658~676 (2019)
- Rebouissou S, "Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression", Hepatology, 64, pp.2047~2061 (2016)
- Kaseb AO, "Molecular profiling of hepatocellular carcinoma using circulating cellfree DNA", Clin Cancer Res, 25, pp.6107~6118 (2019)
- Howell J, "Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma", Eur J Cancer, 116, pp.56~66 (2019)
- Schmitt MW, "Detection of ultra-rare mutations by next-generation sequencing", Proc Natl Acad Sci U S A, 109, pp.14508~14513 (2012)
- Ng CKY, "Genetic profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma patients: a pilot study", Ann Oncol, 29, pp.1286~1291 (2018)